Building the World’s Largest Independent Global Dermatology Company | Flemming Ørnskov of Galderma

Galderma recently made national headlines with a new neurotoxin that promises rapid onset and long duration up to 6 months — and while that may sound too good to be true, the data comes directly from two phase III clinical studies. If that were the only news Galderma CEO Flemming Ørnskov had for us, it would be worthy of an episode in itself. But in this interview with Dr. Grant Stevens, he announces that Galderma will be launching a total of 22 new products this year alone! Tune in to hear all this and more on the latest episode of The Technology of Beauty.